The Leadership Edit Thumbnail European Biotechnology

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: NeoPhore prepares for its first clinical trial, Laverock builds a team for its next financing and GH Research adds late-stage depression expertise.

The Boltz team.

London-based Boltz has raised $110 million (€100 million) in a Series A led by Bessemer Venture Partners to expand its AI platform for designing small-molecule drugs and therapeutic proteins. The financing comes as the company reports rapidly growing adoption among major pharmaceutical companies.

20 pound bill

The British Business Bank has surpassed £1 billion in cumulative support for the U.K. life sciences sector, reaching £1.13 billion (€1.36 billion) through commitments to specialist investment funds and direct investments in biotech and medtech companies.

neuron brain connection

German biotech Priavoid has missed the primary efficacy endpoint in a Phase 2 trial of its oral Alzheimer’s drug PRI-002. However, the company reported encouraging signs of cognitive benefit in longer-term exploratory analyses, leaving the future of its experimental treatment open.

Image credit: Warren Umoh via Unsplash+

U.S. biotech Vertex Pharmaceuticals has extended its drug discovery partnership with Oxford-based Genomics Limited by an additional four years in a deal the U.K. company says could exceed $220 million (€200 million).

disco ball party

Cologne-based DISCO Pharmaceuticals has signed a cancer drug discovery deal with AbbVie, securing $40 million (€36.5 million) upfront and potentially up to $2.5 billion (€2.3 billion) in additional payments. It is the German biotech’s second major pharma partnership this year, following its January agreement with Amgen.

Demis Hassabis

London-based Isomorphic Labs has raised $5 billion (€4.5 billion) in a Series C co-led by Greenoaks and Sequoia Capital, just six months after securing $2.1 billion. The latest financing takes the Alphabet-backed AI drug developer’s disclosed fundraising to $7.7 billion across three rounds since March 2025.

Image credit: Allison Saeng via Unsplash+

Dutch biotech AmyriAD Therapeutics has added a second clinical-stage drug in six weeks, buying worldwide rights to the Alzheimer’s candidate AD04 from Miami-based ADvantage Therapeutics on undisclosed terms. It plans a Phase 2b trial in mild Alzheimer’s disease, though ADvantage’s own European Phase 2b is paused.

Meanwhile in Biotech - European Biotechnology news roundup

This week in our news roundup: Cellectis’ shift toward in vivo gene editing comes with steep workforce cuts, while Sanofi and AstraZeneca add new technologies through deals. Elsewhere, respiratory developers plan a merger, Lithuania’s Biomatter raises funding and Zealand seeks partners for its rare-disease medicines.

commit or quit

Danish biotech Commit Biologics has completed a $60 million (€54 million) seed financing round to advance its first complement-powered immune engager toward clinical trials. The closing follows the nomination of its first drug candidate and several senior appointments as the company prepares to enter the clinic.